Trial Profile
A Repeat Cohort study of SCD-101 in patients with Homozygous Sickle Cell Disease or S/Beta 0 Thalassemia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2017
Price :
$35
*
At a glance
- Drugs SCD 101 (Primary)
- Indications Beta-thalassaemia; Sickle cell anaemia
- Focus Adverse reactions; Therapeutic Use
- 11 Jan 2017 New trial record
- 06 Dec 2016 Results (n=3; as of August 4, 2016) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology